nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—ABCB1—colon cancer	0.367	1	CbGaD
Dapagliflozin—UGT1A9—Irinotecan—colon cancer	0.162	0.378	CbGbCtD
Dapagliflozin—CYP2A6—Fluorouracil—colon cancer	0.0757	0.176	CbGbCtD
Dapagliflozin—CYP2C9—Capecitabine—colon cancer	0.0439	0.102	CbGbCtD
Dapagliflozin—CYP1A2—Fluorouracil—colon cancer	0.0289	0.0672	CbGbCtD
Dapagliflozin—ABCB1—Irinotecan—colon cancer	0.0263	0.0613	CbGbCtD
Dapagliflozin—CYP2C9—Fluorouracil—colon cancer	0.026	0.0606	CbGbCtD
Dapagliflozin—ABCB1—Vincristine—colon cancer	0.023	0.0536	CbGbCtD
Dapagliflozin—CYP3A4—Irinotecan—colon cancer	0.0158	0.0367	CbGbCtD
Dapagliflozin—ABCB1—Methotrexate—colon cancer	0.0139	0.0324	CbGbCtD
Dapagliflozin—CYP3A4—Vincristine—colon cancer	0.0138	0.0321	CbGbCtD
Dapagliflozin—Carcinogenicity—Methotrexate—colon cancer	0.00977	0.0987	CcSEcCtD
Dapagliflozin—SLC5A4—renal system—colon cancer	0.00672	0.108	CbGeAlD
Dapagliflozin—SLC5A4—digestive system—colon cancer	0.00551	0.0886	CbGeAlD
Dapagliflozin—SLC5A2—renal system—colon cancer	0.0051	0.0819	CbGeAlD
Dapagliflozin—SLC5A1—epithelium—colon cancer	0.00416	0.0669	CbGeAlD
Dapagliflozin—SLC5A1—renal system—colon cancer	0.00386	0.0621	CbGeAlD
Dapagliflozin—Hypovolaemia—Irinotecan—colon cancer	0.00381	0.0385	CcSEcCtD
Dapagliflozin—SLC5A2—vagina—colon cancer	0.00369	0.0593	CbGeAlD
Dapagliflozin—Canagliflozin—ABCB1—colon cancer	0.00328	1	CrCbGaD
Dapagliflozin—SLC5A1—digestive system—colon cancer	0.00317	0.0509	CbGeAlD
Dapagliflozin—Angina unstable—Capecitabine—colon cancer	0.00313	0.0316	CcSEcCtD
Dapagliflozin—SLC5A1—vagina—colon cancer	0.0028	0.0449	CbGeAlD
Dapagliflozin—UGT1A9—renal system—colon cancer	0.00243	0.0391	CbGeAlD
Dapagliflozin—UGT2B4—liver—colon cancer	0.00217	0.0349	CbGeAlD
Dapagliflozin—UGT1A9—digestive system—colon cancer	0.00199	0.032	CbGeAlD
Dapagliflozin—UGT2B7—renal system—colon cancer	0.00196	0.0315	CbGeAlD
Dapagliflozin—Serum creatinine increased—Irinotecan—colon cancer	0.00192	0.0194	CcSEcCtD
Dapagliflozin—Lung disorder—Irinotecan—colon cancer	0.00167	0.0169	CcSEcCtD
Dapagliflozin—UGT2B7—digestive system—colon cancer	0.00161	0.0258	CbGeAlD
Dapagliflozin—UGT1A9—liver—colon cancer	0.00149	0.0239	CbGeAlD
Dapagliflozin—Venous thrombosis—Capecitabine—colon cancer	0.00147	0.0148	CcSEcCtD
Dapagliflozin—Extravasation—Vincristine—colon cancer	0.00139	0.014	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Irinotecan—colon cancer	0.00138	0.014	CcSEcCtD
Dapagliflozin—Extravasation—Irinotecan—colon cancer	0.00135	0.0137	CcSEcCtD
Dapagliflozin—Extravasation—Fluorouracil—colon cancer	0.0013	0.0131	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Capecitabine—colon cancer	0.00129	0.013	CcSEcCtD
Dapagliflozin—UGT2B7—liver—colon cancer	0.0012	0.0192	CbGeAlD
Dapagliflozin—Urine output increased—Vincristine—colon cancer	0.0011	0.0111	CcSEcCtD
Dapagliflozin—Neoplasm—Irinotecan—colon cancer	0.00107	0.0108	CcSEcCtD
Dapagliflozin—Fungal infection—Capecitabine—colon cancer	0.00102	0.0103	CcSEcCtD
Dapagliflozin—CYP2A6—vagina—colon cancer	0.00102	0.0163	CbGeAlD
Dapagliflozin—Fracture—Methotrexate—colon cancer	0.00101	0.0102	CcSEcCtD
Dapagliflozin—Multiple fractures—Methotrexate—colon cancer	0.00101	0.0102	CcSEcCtD
Dapagliflozin—Polyuria—Vincristine—colon cancer	0.001	0.0101	CcSEcCtD
Dapagliflozin—Hyponatraemia—Vincristine—colon cancer	0.000884	0.00893	CcSEcCtD
Dapagliflozin—Pain in extremity—Vincristine—colon cancer	0.000881	0.0089	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Irinotecan—colon cancer	0.000875	0.00884	CcSEcCtD
Dapagliflozin—Hyponatraemia—Irinotecan—colon cancer	0.000861	0.0087	CcSEcCtD
Dapagliflozin—CYP2A6—liver—colon cancer	0.000858	0.0138	CbGeAlD
Dapagliflozin—Nocturia—Capecitabine—colon cancer	0.000853	0.00861	CcSEcCtD
Dapagliflozin—ABCB1—blood vessel—colon cancer	0.000837	0.0134	CbGeAlD
Dapagliflozin—Lung disorder—Methotrexate—colon cancer	0.000832	0.0084	CcSEcCtD
Dapagliflozin—Dehydration—Vincristine—colon cancer	0.000819	0.00827	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Irinotecan—colon cancer	0.000804	0.00812	CcSEcCtD
Dapagliflozin—Dehydration—Irinotecan—colon cancer	0.000798	0.00806	CcSEcCtD
Dapagliflozin—CYP1A1—epithelium—colon cancer	0.000784	0.0126	CbGeAlD
Dapagliflozin—Orthostatic hypotension—Irinotecan—colon cancer	0.000783	0.00791	CcSEcCtD
Dapagliflozin—Fungal infection—Methotrexate—colon cancer	0.000762	0.0077	CcSEcCtD
Dapagliflozin—CYP1A2—renal system—colon cancer	0.000738	0.0119	CbGeAlD
Dapagliflozin—Nasopharyngitis—Fluorouracil—colon cancer	0.000735	0.00742	CcSEcCtD
Dapagliflozin—CYP1A1—renal system—colon cancer	0.000727	0.0117	CbGeAlD
Dapagliflozin—Angina pectoris—Irinotecan—colon cancer	0.000722	0.00729	CcSEcCtD
Dapagliflozin—Neoplasm—Capecitabine—colon cancer	0.000715	0.00722	CcSEcCtD
Dapagliflozin—Urine output increased—Capecitabine—colon cancer	0.000715	0.00722	CcSEcCtD
Dapagliflozin—Dysuria—Vincristine—colon cancer	0.000712	0.00719	CcSEcCtD
Dapagliflozin—Angina pectoris—Fluorouracil—colon cancer	0.000692	0.00699	CcSEcCtD
Dapagliflozin—Extravasation—Methotrexate—colon cancer	0.000675	0.00681	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Vincristine—colon cancer	0.000669	0.00676	CcSEcCtD
Dapagliflozin—Phlebitis—Capecitabine—colon cancer	0.000666	0.00673	CcSEcCtD
Dapagliflozin—Myocardial infarction—Vincristine—colon cancer	0.000665	0.00672	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Capecitabine—colon cancer	0.00066	0.00667	CcSEcCtD
Dapagliflozin—Polyuria—Capecitabine—colon cancer	0.000654	0.0066	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Irinotecan—colon cancer	0.000652	0.00658	CcSEcCtD
Dapagliflozin—Renal failure—Irinotecan—colon cancer	0.00065	0.00656	CcSEcCtD
Dapagliflozin—Myocardial infarction—Irinotecan—colon cancer	0.000648	0.00654	CcSEcCtD
Dapagliflozin—Infestation NOS—Fluorouracil—colon cancer	0.000633	0.00639	CcSEcCtD
Dapagliflozin—Infestation—Fluorouracil—colon cancer	0.000633	0.00639	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Fluorouracil—colon cancer	0.000624	0.0063	CcSEcCtD
Dapagliflozin—Myocardial infarction—Fluorouracil—colon cancer	0.000621	0.00627	CcSEcCtD
Dapagliflozin—Urinary tract infection—Fluorouracil—colon cancer	0.000615	0.00621	CcSEcCtD
Dapagliflozin—CYP1A2—digestive system—colon cancer	0.000605	0.00972	CbGeAlD
Dapagliflozin—Thirst—Capecitabine—colon cancer	0.000603	0.00609	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Vincristine—colon cancer	0.000602	0.00608	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Vincristine—colon cancer	0.000599	0.00605	CcSEcCtD
Dapagliflozin—Urethral disorder—Vincristine—colon cancer	0.000597	0.00603	CcSEcCtD
Dapagliflozin—CYP1A1—digestive system—colon cancer	0.000597	0.00959	CbGeAlD
Dapagliflozin—Cerebrovascular accident—Capecitabine—colon cancer	0.000586	0.00592	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Irinotecan—colon cancer	0.000583	0.00589	CcSEcCtD
Dapagliflozin—Hyponatraemia—Capecitabine—colon cancer	0.000576	0.00582	CcSEcCtD
Dapagliflozin—CYP2C9—digestive system—colon cancer	0.000574	0.00923	CbGeAlD
Dapagliflozin—Pain in extremity—Capecitabine—colon cancer	0.000574	0.0058	CcSEcCtD
Dapagliflozin—Vaginal infection—Methotrexate—colon cancer	0.000556	0.00561	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Capecitabine—colon cancer	0.000538	0.00543	CcSEcCtD
Dapagliflozin—Dehydration—Capecitabine—colon cancer	0.000534	0.00539	CcSEcCtD
Dapagliflozin—CYP3A4—renal system—colon cancer	0.000534	0.00858	CbGeAlD
Dapagliflozin—Urine output increased—Methotrexate—colon cancer	0.000532	0.00538	CcSEcCtD
Dapagliflozin—Neoplasm—Methotrexate—colon cancer	0.000532	0.00538	CcSEcCtD
Dapagliflozin—CYP1A1—vagina—colon cancer	0.000527	0.00847	CbGeAlD
Dapagliflozin—CYP2D6—renal system—colon cancer	0.000525	0.00844	CbGeAlD
Dapagliflozin—Orthostatic hypotension—Capecitabine—colon cancer	0.000524	0.0053	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Capecitabine—colon cancer	0.000513	0.00518	CcSEcCtD
Dapagliflozin—Back pain—Vincristine—colon cancer	0.000513	0.00518	CcSEcCtD
Dapagliflozin—Back pain—Irinotecan—colon cancer	0.0005	0.00505	CcSEcCtD
Dapagliflozin—ABCB1—embryo—colon cancer	0.000499	0.00802	CbGeAlD
Dapagliflozin—Influenza—Capecitabine—colon cancer	0.000496	0.00501	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Methotrexate—colon cancer	0.000491	0.00496	CcSEcCtD
Dapagliflozin—Polyuria—Methotrexate—colon cancer	0.000487	0.00492	CcSEcCtD
Dapagliflozin—Angina pectoris—Capecitabine—colon cancer	0.000483	0.00488	CcSEcCtD
Dapagliflozin—Dysuria—Capecitabine—colon cancer	0.000464	0.00469	CcSEcCtD
Dapagliflozin—Hypertension—Vincristine—colon cancer	0.000458	0.00462	CcSEcCtD
Dapagliflozin—CYP1A2—liver—colon cancer	0.000451	0.00724	CbGeAlD
Dapagliflozin—Hypertension—Irinotecan—colon cancer	0.000446	0.0045	CcSEcCtD
Dapagliflozin—CYP1A1—liver—colon cancer	0.000445	0.00714	CbGeAlD
Dapagliflozin—Infestation NOS—Capecitabine—colon cancer	0.000442	0.00447	CcSEcCtD
Dapagliflozin—Infestation—Capecitabine—colon cancer	0.000442	0.00447	CcSEcCtD
Dapagliflozin—CYP3A4—digestive system—colon cancer	0.000438	0.00704	CbGeAlD
Dapagliflozin—Acute coronary syndrome—Capecitabine—colon cancer	0.000436	0.0044	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Methotrexate—colon cancer	0.000436	0.0044	CcSEcCtD
Dapagliflozin—Renal failure—Capecitabine—colon cancer	0.000435	0.00439	CcSEcCtD
Dapagliflozin—Discomfort—Irinotecan—colon cancer	0.000435	0.00439	CcSEcCtD
Dapagliflozin—Myocardial infarction—Capecitabine—colon cancer	0.000434	0.00438	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Vincristine—colon cancer	0.000433	0.00437	CcSEcCtD
Dapagliflozin—Oedema—Vincristine—colon cancer	0.000433	0.00437	CcSEcCtD
Dapagliflozin—CYP2D6—digestive system—colon cancer	0.000431	0.00692	CbGeAlD
Dapagliflozin—Infection—Vincristine—colon cancer	0.00043	0.00434	CcSEcCtD
Dapagliflozin—Urinary tract infection—Capecitabine—colon cancer	0.00043	0.00434	CcSEcCtD
Dapagliflozin—CYP2C9—liver—colon cancer	0.000428	0.00687	CbGeAlD
Dapagliflozin—Oedema—Irinotecan—colon cancer	0.000422	0.00426	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Irinotecan—colon cancer	0.000422	0.00426	CcSEcCtD
Dapagliflozin—Infection—Irinotecan—colon cancer	0.000419	0.00423	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Vincristine—colon cancer	0.000419	0.00423	CcSEcCtD
Dapagliflozin—Discomfort—Fluorouracil—colon cancer	0.000416	0.0042	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Irinotecan—colon cancer	0.000408	0.00412	CcSEcCtD
Dapagliflozin—ABCB1—epithelium—colon cancer	0.000407	0.00655	CbGeAlD
Dapagliflozin—Hypotension—Vincristine—colon cancer	0.000405	0.00409	CcSEcCtD
Dapagliflozin—Oedema—Fluorouracil—colon cancer	0.000404	0.00408	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Fluorouracil—colon cancer	0.000404	0.00408	CcSEcCtD
Dapagliflozin—Infection—Fluorouracil—colon cancer	0.000401	0.00405	CcSEcCtD
Dapagliflozin—Hypotension—Irinotecan—colon cancer	0.000394	0.00398	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Capecitabine—colon cancer	0.000392	0.00396	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Capecitabine—colon cancer	0.00039	0.00394	CcSEcCtD
Dapagliflozin—Urethral disorder—Capecitabine—colon cancer	0.000389	0.00393	CcSEcCtD
Dapagliflozin—ABCB1—renal system—colon cancer	0.000378	0.00607	CbGeAlD
Dapagliflozin—Hypotension—Fluorouracil—colon cancer	0.000377	0.00381	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vincristine—colon cancer	0.000374	0.00377	CcSEcCtD
Dapagliflozin—Constipation—Vincristine—colon cancer	0.00037	0.00374	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Irinotecan—colon cancer	0.000364	0.00368	CcSEcCtD
Dapagliflozin—Constipation—Irinotecan—colon cancer	0.000361	0.00364	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000349	0.00352	CcSEcCtD
Dapagliflozin—Malnutrition—Capecitabine—colon cancer	0.000346	0.00349	CcSEcCtD
Dapagliflozin—Dysuria—Methotrexate—colon cancer	0.000345	0.00349	CcSEcCtD
Dapagliflozin—Body temperature increased—Vincristine—colon cancer	0.000342	0.00346	CcSEcCtD
Dapagliflozin—CYP1A1—lymph node—colon cancer	0.000341	0.00548	CbGeAlD
Dapagliflozin—Back pain—Capecitabine—colon cancer	0.000334	0.00338	CcSEcCtD
Dapagliflozin—Body temperature increased—Irinotecan—colon cancer	0.000333	0.00337	CcSEcCtD
Dapagliflozin—Infestation NOS—Methotrexate—colon cancer	0.000329	0.00333	CcSEcCtD
Dapagliflozin—Infestation—Methotrexate—colon cancer	0.000329	0.00333	CcSEcCtD
Dapagliflozin—CYP3A4—liver—colon cancer	0.000326	0.00524	CbGeAlD
Dapagliflozin—Renal failure—Methotrexate—colon cancer	0.000324	0.00327	CcSEcCtD
Dapagliflozin—CYP2D6—liver—colon cancer	0.000321	0.00516	CbGeAlD
Dapagliflozin—Urticaria—Fluorouracil—colon cancer	0.000321	0.00324	CcSEcCtD
Dapagliflozin—Body temperature increased—Fluorouracil—colon cancer	0.000319	0.00322	CcSEcCtD
Dapagliflozin—Hypersensitivity—Vincristine—colon cancer	0.000319	0.00322	CcSEcCtD
Dapagliflozin—ABCB1—lymphoid tissue—colon cancer	0.000314	0.00504	CbGeAlD
Dapagliflozin—Hypersensitivity—Irinotecan—colon cancer	0.000311	0.00314	CcSEcCtD
Dapagliflozin—ABCB1—digestive system—colon cancer	0.00031	0.00498	CbGeAlD
Dapagliflozin—Hypertension—Capecitabine—colon cancer	0.000298	0.00301	CcSEcCtD
Dapagliflozin—Hypersensitivity—Fluorouracil—colon cancer	0.000297	0.003	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000292	0.00295	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Methotrexate—colon cancer	0.000292	0.00295	CcSEcCtD
Dapagliflozin—Discomfort—Capecitabine—colon cancer	0.000291	0.00294	CcSEcCtD
Dapagliflozin—Urethral disorder—Methotrexate—colon cancer	0.00029	0.00293	CcSEcCtD
Dapagliflozin—Dizziness—Vincristine—colon cancer	0.000286	0.00289	CcSEcCtD
Dapagliflozin—ABCB1—bone marrow—colon cancer	0.000286	0.00459	CbGeAlD
Dapagliflozin—Oedema—Capecitabine—colon cancer	0.000282	0.00285	CcSEcCtD
Dapagliflozin—Infection—Capecitabine—colon cancer	0.00028	0.00283	CcSEcCtD
Dapagliflozin—Dizziness—Irinotecan—colon cancer	0.000279	0.00282	CcSEcCtD
Dapagliflozin—Skin disorder—Capecitabine—colon cancer	0.000274	0.00277	CcSEcCtD
Dapagliflozin—ABCB1—vagina—colon cancer	0.000274	0.0044	CbGeAlD
Dapagliflozin—Rash—Vincristine—colon cancer	0.000273	0.00276	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Capecitabine—colon cancer	0.000273	0.00275	CcSEcCtD
Dapagliflozin—Dermatitis—Vincristine—colon cancer	0.000273	0.00275	CcSEcCtD
Dapagliflozin—Headache—Vincristine—colon cancer	0.000271	0.00274	CcSEcCtD
Dapagliflozin—Dizziness—Fluorouracil—colon cancer	0.000267	0.0027	CcSEcCtD
Dapagliflozin—Rash—Irinotecan—colon cancer	0.000266	0.00268	CcSEcCtD
Dapagliflozin—Dermatitis—Irinotecan—colon cancer	0.000266	0.00268	CcSEcCtD
Dapagliflozin—Headache—Irinotecan—colon cancer	0.000264	0.00267	CcSEcCtD
Dapagliflozin—Hypotension—Capecitabine—colon cancer	0.000264	0.00266	CcSEcCtD
Dapagliflozin—Malnutrition—Methotrexate—colon cancer	0.000257	0.0026	CcSEcCtD
Dapagliflozin—Nausea—Vincristine—colon cancer	0.000257	0.0026	CcSEcCtD
Dapagliflozin—Rash—Fluorouracil—colon cancer	0.000255	0.00257	CcSEcCtD
Dapagliflozin—Dermatitis—Fluorouracil—colon cancer	0.000254	0.00257	CcSEcCtD
Dapagliflozin—Headache—Fluorouracil—colon cancer	0.000253	0.00255	CcSEcCtD
Dapagliflozin—Nausea—Irinotecan—colon cancer	0.00025	0.00253	CcSEcCtD
Dapagliflozin—Back pain—Methotrexate—colon cancer	0.000249	0.00251	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Capecitabine—colon cancer	0.000244	0.00246	CcSEcCtD
Dapagliflozin—Constipation—Capecitabine—colon cancer	0.000241	0.00244	CcSEcCtD
Dapagliflozin—Nausea—Fluorouracil—colon cancer	0.00024	0.00242	CcSEcCtD
Dapagliflozin—ABCB1—liver—colon cancer	0.000231	0.00371	CbGeAlD
Dapagliflozin—Urticaria—Capecitabine—colon cancer	0.000224	0.00226	CcSEcCtD
Dapagliflozin—Body temperature increased—Capecitabine—colon cancer	0.000223	0.00225	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000218	0.0022	CcSEcCtD
Dapagliflozin—Discomfort—Methotrexate—colon cancer	0.000216	0.00219	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Methotrexate—colon cancer	0.00021	0.00212	CcSEcCtD
Dapagliflozin—Infection—Methotrexate—colon cancer	0.000209	0.00211	CcSEcCtD
Dapagliflozin—Hypersensitivity—Capecitabine—colon cancer	0.000208	0.0021	CcSEcCtD
Dapagliflozin—Skin disorder—Methotrexate—colon cancer	0.000204	0.00206	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Methotrexate—colon cancer	0.000203	0.00205	CcSEcCtD
Dapagliflozin—Hypotension—Methotrexate—colon cancer	0.000196	0.00198	CcSEcCtD
Dapagliflozin—Dizziness—Capecitabine—colon cancer	0.000187	0.00188	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Methotrexate—colon cancer	0.000181	0.00183	CcSEcCtD
Dapagliflozin—Rash—Capecitabine—colon cancer	0.000178	0.0018	CcSEcCtD
Dapagliflozin—Dermatitis—Capecitabine—colon cancer	0.000178	0.0018	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—colon cancer	0.000177	0.00284	CbGeAlD
Dapagliflozin—Headache—Capecitabine—colon cancer	0.000177	0.00179	CcSEcCtD
Dapagliflozin—Nausea—Capecitabine—colon cancer	0.000168	0.00169	CcSEcCtD
Dapagliflozin—Urticaria—Methotrexate—colon cancer	0.000167	0.00169	CcSEcCtD
Dapagliflozin—Body temperature increased—Methotrexate—colon cancer	0.000166	0.00168	CcSEcCtD
Dapagliflozin—Hypersensitivity—Methotrexate—colon cancer	0.000155	0.00156	CcSEcCtD
Dapagliflozin—Dizziness—Methotrexate—colon cancer	0.000139	0.0014	CcSEcCtD
Dapagliflozin—Rash—Methotrexate—colon cancer	0.000132	0.00134	CcSEcCtD
Dapagliflozin—Dermatitis—Methotrexate—colon cancer	0.000132	0.00134	CcSEcCtD
Dapagliflozin—Headache—Methotrexate—colon cancer	0.000132	0.00133	CcSEcCtD
Dapagliflozin—Nausea—Methotrexate—colon cancer	0.000125	0.00126	CcSEcCtD
Dapagliflozin—CYP2A6—Metabolism—CA7—colon cancer	9.34e-05	0.00239	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	9.1e-05	0.00233	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ODC1—colon cancer	9.03e-05	0.00231	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CHST5—colon cancer	9.03e-05	0.00231	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—ABCB1—colon cancer	8.95e-05	0.00229	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	8.95e-05	0.00229	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—TYMS—colon cancer	8.79e-05	0.00225	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	8.51e-05	0.00218	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—EP300—colon cancer	8.51e-05	0.00218	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—FGFR3—colon cancer	8.39e-05	0.00215	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	8.28e-05	0.00212	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—SRC—colon cancer	8.28e-05	0.00212	CbGpPWpGaD
Dapagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	8.15e-05	0.00209	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	8.06e-05	0.00207	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—colon cancer	7.96e-05	0.00204	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—APC—colon cancer	7.71e-05	0.00197	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	7.66e-05	0.00196	CbGpPWpGaD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	7.61e-05	0.00195	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—MYC—colon cancer	7.42e-05	0.0019	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	7.4e-05	0.0019	CbGpPWpGaD
Dapagliflozin—UGT1A9—PPARA activates gene expression—EP300—colon cancer	7.38e-05	0.00189	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ODC1—colon cancer	7.34e-05	0.00188	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CHST5—colon cancer	7.34e-05	0.00188	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—colon cancer	7.26e-05	0.00186	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	7.26e-05	0.00186	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—BRAF—colon cancer	7.24e-05	0.00186	CbGpPWpGaD
Dapagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	7.22e-05	0.00185	CbGpPWpGaD
Dapagliflozin—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	7.14e-05	0.00183	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CA7—colon cancer	6.96e-05	0.00178	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—colon cancer	6.85e-05	0.00176	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—ABCB1—colon cancer	6.79e-05	0.00174	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—ABCB1—colon cancer	6.79e-05	0.00174	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—TYMS—colon cancer	6.66e-05	0.00171	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—TYMS—colon cancer	6.66e-05	0.00171	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—colon cancer	6.53e-05	0.00167	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—PPARG—colon cancer	6.48e-05	0.00166	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—FGFR3—colon cancer	6.36e-05	0.00163	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—FGFR3—colon cancer	6.36e-05	0.00163	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—colon cancer	6.34e-05	0.00162	CbGpPWpGaD
Dapagliflozin—UGT2B7—NRF2 pathway—TGFB1—colon cancer	6.29e-05	0.00161	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PPARG—colon cancer	6.23e-05	0.0016	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	6.13e-05	0.00157	CbGpPWpGaD
Dapagliflozin—CYP1A2—Arachidonic acid metabolism—PTGS2—colon cancer	6.11e-05	0.00156	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PTGS2—colon cancer	5.85e-05	0.0015	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—APC—colon cancer	5.84e-05	0.0015	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—APC—colon cancer	5.84e-05	0.0015	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—colon cancer	5.83e-05	0.00149	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—colon cancer	5.7e-05	0.00146	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ODC1—colon cancer	5.66e-05	0.00145	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CHST5—colon cancer	5.66e-05	0.00145	CbGpPWpGaD
Dapagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	5.63e-05	0.00144	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CA7—colon cancer	5.56e-05	0.00142	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—BRAF—colon cancer	5.49e-05	0.00141	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—BRAF—colon cancer	5.49e-05	0.00141	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—colon cancer	5.43e-05	0.00139	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—colon cancer	5.43e-05	0.00139	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—SRC—colon cancer	5.28e-05	0.00135	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—colon cancer	5.28e-05	0.00135	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—ABCB1—colon cancer	5.24e-05	0.00134	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CA7—colon cancer	5.24e-05	0.00134	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CTNNB1—colon cancer	5.24e-05	0.00134	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CA7—colon cancer	5.19e-05	0.00133	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—TYMS—colon cancer	5.15e-05	0.00132	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—colon cancer	5.14e-05	0.00132	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—TGFB1—colon cancer	5.11e-05	0.00131	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—CDKN1A—colon cancer	5.11e-05	0.00131	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	5.09e-05	0.0013	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—colon cancer	5.08e-05	0.0013	CbGpPWpGaD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	4.98e-05	0.00127	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—CASP3—colon cancer	4.92e-05	0.00126	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PTGS2—colon cancer	4.9e-05	0.00126	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—EP300—colon cancer	4.87e-05	0.00125	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	4.82e-05	0.00124	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—SRC—colon cancer	4.73e-05	0.00121	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	4.73e-05	0.00121	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PPARG—colon cancer	4.72e-05	0.00121	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PPARG—colon cancer	4.72e-05	0.00121	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	4.72e-05	0.00121	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	4.7e-05	0.0012	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	4.63e-05	0.00119	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	4.63e-05	0.00119	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NRAS—colon cancer	4.55e-05	0.00117	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	4.52e-05	0.00116	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CA7—colon cancer	4.43e-05	0.00114	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PTGS2—colon cancer	4.43e-05	0.00114	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PTGS2—colon cancer	4.43e-05	0.00114	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	4.37e-05	0.00112	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—colon cancer	4.37e-05	0.00112	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—MYC—colon cancer	4.24e-05	0.00109	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—EP300—colon cancer	4.24e-05	0.00109	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—TGFB1—colon cancer	4.23e-05	0.00108	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CHST5—colon cancer	4.21e-05	0.00108	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ODC1—colon cancer	4.21e-05	0.00108	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—VEGFA—colon cancer	4.18e-05	0.00107	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—colon cancer	4.15e-05	0.00106	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—EGFR—colon cancer	4.15e-05	0.00106	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—EP300—colon cancer	4.08e-05	0.00104	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CTNNB1—colon cancer	3.97e-05	0.00102	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CTNNB1—colon cancer	3.97e-05	0.00102	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—TGFB1—colon cancer	3.94e-05	0.00101	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—KRAS—colon cancer	3.92e-05	0.001	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CDKN1A—colon cancer	3.88e-05	0.000993	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CDKN1A—colon cancer	3.88e-05	0.000993	CbGpPWpGaD
Dapagliflozin—ABCB1—Allograft Rejection—TGFB1—colon cancer	3.83e-05	0.000982	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	3.72e-05	0.000952	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PTGS2—colon cancer	3.71e-05	0.000951	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PTGS2—colon cancer	3.71e-05	0.000951	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EP300—colon cancer	3.69e-05	0.000945	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EP300—colon cancer	3.69e-05	0.000945	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PPARG—colon cancer	3.64e-05	0.000934	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PIK3CA—colon cancer	3.6e-05	0.000922	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—SRC—colon cancer	3.59e-05	0.000919	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—SRC—colon cancer	3.59e-05	0.000919	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NRAS—colon cancer	3.45e-05	0.000884	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NRAS—colon cancer	3.45e-05	0.000884	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	3.45e-05	0.000883	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CA7—colon cancer	3.42e-05	0.000877	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CHST5—colon cancer	3.37e-05	0.000862	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ODC1—colon cancer	3.37e-05	0.000862	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HRAS—colon cancer	3.33e-05	0.000853	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—MYC—colon cancer	3.21e-05	0.000823	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—MYC—colon cancer	3.21e-05	0.000823	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TGFB1—colon cancer	3.21e-05	0.000821	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TGFB1—colon cancer	3.21e-05	0.000821	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ODC1—colon cancer	3.17e-05	0.000813	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CHST5—colon cancer	3.17e-05	0.000813	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ODC1—colon cancer	3.14e-05	0.000806	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CHST5—colon cancer	3.14e-05	0.000806	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—EGFR—colon cancer	3.14e-05	0.000805	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—EGFR—colon cancer	3.14e-05	0.000805	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—EP300—colon cancer	3.09e-05	0.000791	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—EP300—colon cancer	3.09e-05	0.000791	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	3.08e-05	0.000789	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.03e-05	0.000776	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PIK3CA—colon cancer	3.01e-05	0.000772	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—KRAS—colon cancer	2.97e-05	0.000761	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—KRAS—colon cancer	2.97e-05	0.000761	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—AKT1—colon cancer	2.94e-05	0.000753	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTGS2—colon cancer	2.87e-05	0.000735	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	2.86e-05	0.000732	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PIK3CA—colon cancer	2.73e-05	0.000699	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PIK3CA—colon cancer	2.73e-05	0.000699	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ODC1—colon cancer	2.69e-05	0.000688	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CHST5—colon cancer	2.69e-05	0.000688	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	2.62e-05	0.000671	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HRAS—colon cancer	2.52e-05	0.000647	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HRAS—colon cancer	2.52e-05	0.000647	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—AKT1—colon cancer	2.46e-05	0.000631	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	2.43e-05	0.000622	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—ABCB1—colon cancer	2.39e-05	0.000611	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—EP300—colon cancer	2.38e-05	0.000611	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.38e-05	0.00061	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	2.37e-05	0.000606	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TYMS—colon cancer	2.34e-05	0.0006	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	2.34e-05	0.0006	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	2.29e-05	0.000586	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PIK3CA—colon cancer	2.28e-05	0.000585	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PIK3CA—colon cancer	2.28e-05	0.000585	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—AKT1—colon cancer	2.23e-05	0.000571	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—AKT1—colon cancer	2.23e-05	0.000571	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	2.18e-05	0.000558	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	2.12e-05	0.000542	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ODC1—colon cancer	2.07e-05	0.000531	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CHST5—colon cancer	2.07e-05	0.000531	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	2.06e-05	0.000528	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.98e-05	0.000508	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—ABCB1—colon cancer	1.94e-05	0.000497	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TYMS—colon cancer	1.9e-05	0.000488	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.9e-05	0.000486	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.89e-05	0.000485	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AKT1—colon cancer	1.87e-05	0.000478	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AKT1—colon cancer	1.87e-05	0.000478	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.86e-05	0.000475	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PIK3CA—colon cancer	1.76e-05	0.000452	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.75e-05	0.000449	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.74e-05	0.000446	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPARG—colon cancer	1.66e-05	0.000425	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.61e-05	0.000413	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.56e-05	0.000399	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—ABCB1—colon cancer	1.49e-05	0.000383	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TYMS—colon cancer	1.47e-05	0.000376	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.47e-05	0.000376	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—colon cancer	1.44e-05	0.000369	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.37e-05	0.000351	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARG—colon cancer	1.35e-05	0.000346	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	1.32e-05	0.000337	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—colon cancer	1.31e-05	0.000335	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.3e-05	0.000333	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.14e-05	0.000292	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ABCB1—colon cancer	1.11e-05	0.000285	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.11e-05	0.000284	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMS—colon cancer	1.09e-05	0.00028	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—EP300—colon cancer	1.09e-05	0.000278	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—colon cancer	1.06e-05	0.000272	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—colon cancer	1.04e-05	0.000266	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.02e-05	0.000262	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—EP300—colon cancer	8.83e-06	0.000226	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMS—colon cancer	8.74e-06	0.000224	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.73e-06	0.000224	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	8.49e-06	0.000218	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.42e-06	0.000216	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ABCB1—colon cancer	8.38e-06	0.000215	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ABCB1—colon cancer	8.31e-06	0.000213	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMS—colon cancer	8.23e-06	0.000211	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—colon cancer	8.18e-06	0.00021	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMS—colon cancer	8.16e-06	0.000209	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—colon cancer	8.03e-06	0.000206	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—colon cancer	7.75e-06	0.000198	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.26e-06	0.000186	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ABCB1—colon cancer	7.1e-06	0.000182	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMS—colon cancer	6.97e-06	0.000179	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—EP300—colon cancer	6.8e-06	0.000174	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—colon cancer	6.56e-06	0.000168	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—colon cancer	6.53e-06	0.000167	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.28e-06	0.000161	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—colon cancer	6.19e-06	0.000159	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—colon cancer	6.09e-06	0.000156	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—colon cancer	5.83e-06	0.000149	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—colon cancer	5.78e-06	0.000148	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCB1—colon cancer	5.48e-06	0.00014	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMS—colon cancer	5.38e-06	0.000138	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.37e-06	0.000138	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—colon cancer	5.33e-06	0.000137	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—EP300—colon cancer	5.07e-06	0.00013	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—colon cancer	5.03e-06	0.000129	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—colon cancer	4.94e-06	0.000127	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—colon cancer	4.87e-06	0.000125	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—colon cancer	4.59e-06	0.000118	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—colon cancer	4.55e-06	0.000116	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—colon cancer	4.11e-06	0.000105	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—EP300—colon cancer	4.05e-06	0.000104	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—colon cancer	3.89e-06	9.96e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—EP300—colon cancer	3.82e-06	9.77e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—colon cancer	3.81e-06	9.77e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—EP300—colon cancer	3.78e-06	9.69e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—colon cancer	3.75e-06	9.61e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—EP300—colon cancer	3.23e-06	8.28e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—colon cancer	3.06e-06	7.85e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—colon cancer	3e-06	7.68e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—colon cancer	2.99e-06	7.67e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—colon cancer	2.82e-06	7.23e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—colon cancer	2.8e-06	7.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—EP300—colon cancer	2.49e-06	6.39e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—colon cancer	2.45e-06	6.27e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—colon cancer	2.39e-06	6.12e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—colon cancer	2.31e-06	5.91e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—colon cancer	2.29e-06	5.86e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—colon cancer	1.95e-06	5e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—colon cancer	1.85e-06	4.73e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—colon cancer	1.51e-06	3.86e-05	CbGpPWpGaD
